Filing Flows › Health Care › Omeros (OMER)
Omeros (OMER) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Omeros (OMER) Q2 2026 earnings results →
Q2 2026 46¢ of every $1 of revenue kept as net profit · operating margin 0.3%
Omeros made $28.5M in Q2 2026. Operating margin 0.3%, net earnings $13.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $28.5M in Q2 2026, up 188% from the previous quarter.
Operating profit was $74K, a 0.3% margin. Net earnings were $13.2M. The effective tax rate was 0.2%. Non-operating items added $13.2M, 99% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $4.1M, 31% of net earnings. Non-cash charges added back $193K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $10.9M. Capital expenditures of $45K left free cash flow of $4.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $28.5M | — | 0.3% | $13.2M | $4.1M |
| Q1 2026 | 10-Q | May 13, 2026 | $9.9M | — | -176.1% | $56.1M | −$14.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Omeros
Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Our complement-targeted product, product candidates, and therapeutic programs are primarily focused on diseases and disorders associated with the lectin and/or alternative pathways of complement. Our lectin pathway program includes inhibitors of mannan-binding lectin-associated serine protease 2 (“MASP-2”) and our alternative pathway program includes inhibitors of mannan-binding lectin-associated serine protease 3 (“MASP-3”).
In its own words, from its 10-K, filed Mar 31, 2026.
Omeros against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: 0.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OMER Omeros | Q2 2026 | $28.5M | — | 0.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Omeros 10-Q on SEC EDGAR · CIK 1285819 · Pharmaceutical Preparations
13F: who owns OMER and who is buying
More on OMER
History
Every quarter: Q2 2026 results · Q1 2026 results